Caplin Point Laboratories Q2 Results 2026 (FY27): Revenue ₹629.84 Cr, PAT ₹182.35 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #21 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Caplin Point Laboratories Ltd Q2 FY27 key numbers
- Revenue
- Total Revenue for Q2 FY27: ₹663.13 crore, up 17.5% YoY.
As stated in Caplin Point Laboratories Ltd's Q2 FY27 investor presentation · published 12 Nov 2026. Reported figures, not investment advice.
Based on Caplin Point Laboratories Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Revenue from Operations: ₹629.84 crore, up 17.9% YoY (compared to ₹534.04 crore in Q2 FY26). Q2 FY27 Financials:.
From Caplin Point Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 12 Nov 2026.
How did Caplin Point Laboratories' revenue grow in the September 2026 quarter?
- Q2 FY27 Revenue from Operations: ₹629.84 crore, up 17.9% YoY (compared to ₹534.04 crore in Q2 FY26).
- Total Revenue for Q2 FY27: ₹663.13 crore, up 17.5% YoY.
- H1 FY27 Revenue from Operations: ₹1,240.20 crore, up 18.8% YoY.
- H1 FY27 Total Revenue: ₹1,307.04 crore, up 19.1% YoY.
2 more points from Caplin Point Laboratories Ltd's call on revenue
Create a free account to keep reading this call
What happened to Caplin Point Laboratories' margins in Q2 FY27?
See what Caplin Point Laboratories Ltd said on profitability & margins — free account, 30 seconds.
What capex is Caplin Point Laboratories planning?
2 more points from Caplin Point Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Caplin Point Laboratories raising money or cutting debt?
See what Caplin Point Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Caplin Point Laboratories' order book?
See what Caplin Point Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Caplin Point Laboratories Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹600 Cr, net profit ₹173 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsRevenue ₹3770 Cr · PAT ₹1,127 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Caplin Point Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Alkem Lab (Q2 FY27)
Total Revenue from Operations in Q2 FY27: ₹45,520 million, up 13.8% YoY. Key investor presentation takeaways from Alkem Laboratories Ltd's Q2 FY27 investor pres
- Ortin Global (Q2 FY27)
This represents a year-on-year increase of Rs 1.74 lakhs (approximately 124.3% increase). Key results statement takeaways from Ortin Global Ltd's Q2 FY27 result
- Bal Pharma (Q2 FY27)
Revenue from operations (Consolidated) for Q2 FY 2026-27: ₹8,994.69 lakhs, up from ₹7,402.49 lakhs in Q2 FY 2025-26, reflecting a year-on-year increase of…
- Bafna Pharmaceuticals (Q2 FY27)
INR 3,546.82 Lakhs, approximately 34.4% increase. Key results statement takeaways from Bafna Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Caplin Point Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Caplin Point Laboratories Ltd Q2 FY27 results?
Q2 FY27 Revenue from Operations: ₹629.84 crore, up 17.9% YoY (compared to ₹534.04 crore in Q2 FY26). Q2 FY27 Financials:.
What is Caplin Point Laboratories Ltd share price analysis?
Caplin Point Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 28.8 with a market cap of ₹19,160 Cr. Investors should review the full earnings analysis for detailed insights.
Is Caplin Point Laboratories Ltd planning capital expenditure?
Total enhanced Capex budget: ₹1000+ Crores, financed solely through internal accruals, with ~50% nearing completion.
Keep Caplin Point Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.